Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells

International Reviews of Immunology

Volumn 36, Issue 2, 2017, Pages 57-73

  Tartey, Sarang ^a,b   Takeuchi, Osamu ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT   (Japan)

Author keywords

inflammation; Pathogen recognition; therapeutics; TLR signaling; Toll like receptor; tumor immunity

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; IMMUNOLOGICAL ADJUVANT; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3 TICAM 1; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; PATHOGEN ASSOCIATED MOLECULAR PATTERN;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; DISEASES; DRUG TARGETING; FUTUROLOGY; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASM; MICROORGANISM DETECTION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSOR; TUMOR IMMUNITY; ANIMAL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATHOGEN-ASSOCIATED MOLECULAR PATTERN MOLECULES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 85014338689     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.1080/08830185.2016.1261318     Document Type: Review

References (152)

1. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140(6):805–820.
2. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4(7):499–511.
3. Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86(6):973–983.
4. Hashimoto C, Hudson KL, Anderson KV. The toll gene of drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988;52(2):269–279.
5. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice:mutations in Tlr4 gene. Science 1998;282(5396):2085–2088.
6. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge:Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide:evidence for TLR4 as the Lps gene product. J Immunol 1999;162(7):3749–3752.
7. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388(6640):394–397.
8. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004;430(6996):257–263.
9. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity:update on Toll-like receptors. Nat Immunol 2010;11(5):373–384.
10. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335–376.
11. Liew FY, Xu D, Brint EK, et al. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005;5(6):446–458.
12. Takeuchi O, Hoshino K, Kawai T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11(4):443–451.
13. Park BS, Song DH, Kim HM, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009;458(7242):1191–1195.
14. Uematsu S, Fujimoto SK, Jang MH et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol 2008;9(7):769–776.
15. Uematsu S, Jang MH, Chevrier N, et al. Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol 2006;7(8):868–874.
16. Yarovinsky F, Zhang D, Andersen JF, et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 2005;308(5728):1626–1629.
17. Koblansky AA, Jankovic D, Oh H, et al. Recognition of profilin by Toll-like receptor 12 is critical for host resistance to Toxoplasma gondii. Immunity 2013;38(1):119–130.
18. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783–801.
19. Mancuso G, Bambuzza M, Midiri A, et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 2009;10(6):587–594.
20. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408(6813):740–745.
21. Hidmark A, von Saint Paul A, Dalpke AH. Cutting edge:TLR13 is a receptor for bacterial RNA. J Immunol 2012;189(6):2717–2721.
22. Oldenburg M, Kruger A, Ferstl R, et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 2012;337(6098):1111–1115.
23. Shi Z, Cai Z, Sanchez A, et al. A novel Toll-like receptor that recognizes vesicular stomatitis virus. J Biol Chem 2011;286(6):4517–4524.
24. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002;298(5595):1025–1029.
25. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279(9):7370–7377.
26. Guillot L, Valloy V, McCormack FX, et al. Cutting edge:the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002;168(12):5989–5992.
27. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J Immunol 2001;167(5):2887–2894.
28. Okamura Y, Wtari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001;276(13):10229–10233.
29. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195(1):99–111.
30. Oppenheim JJ, Yang D. Alarmins:chemotactic activators of immune responses. Curr Opin Immunol 2005;17(4):359–365.
31. Shichita T, Hasegawa E, Kimura A, et al. Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med 2012;18(6):911–917.
32. Shirey KA, Lai W, Scott AJ, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 2013;497(7450):498–502.
33. Reilly M, Miller RM, Thomson, MH, et al. Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody. Clin Pharmacol Ther 2013;94(5):593–600.
34. Lord KA. Hoffman-Liebermann B, Liebermann DA. Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene 1990;5(7):1095–1097.
35. Muzio M, Ni J, Feng P, et al. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997;278(5343):1612–1615.
36. Wesche H, Henzel WJ, Shillinglaw W, et al. MyD88:an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997;7(6):837–847.
37. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 2010;465(7300):885–890.
38. Yamamoto M, Okamoto T, Takeda K, et al. Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat Immunol 2006;7(9):962–970.
39. Tseng PH, Matsuzawa A, Zhang W, et al. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol 2010;11(1):70–75.
40. Smale ST, Natoli G. Transcriptional control of inflammatory responses. Cold Spring Harb Perspect Biol 2014;6(11):a016261.
41. Smale ST, Tarakhovsky A, and Natoli G. Chromatin contributions to the regulation of innate immunity. Annu Rev Immunol 2014;32:489–511.
42. Tartey S, Matsushita K, Vandenbon A, et al. Akirin2 is critical for inducing inflammatory genes by bridging IkappaB-zeta and the SWI/SNF complex. EMBO J 2014;33(20):2332–2348.
43. Tartey S, Takeuchi O. Chromatin remodeling and transcriptional control in innate immunity:emergence of Akirin2 as a novel player. Biomolecules 2015;5(3):1618–1633.
44. Bonnay F, Nguyen XH, Cohen-Berros E, et al. Akirin specifies NF-kappaB selectivity of Drosophila innate immune response via chromatin remodeling. EMBO J 2014;33(20):2349–2362.
45. Tartey S, Matsushita K, Imamura T, et al. Essential function for the nuclear protein Akirin2 in B cell activation and humoral immune responses. J Immunol 2015;195(2):519–527.
46. Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 2006;24(1):93–103.
47. Ishii KJ, Coban C, Kato H, et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006;7(1):40–48.
48. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008;455(7213):674–678.
49. Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007;448(7152):501–505.
50. Ablasser A, Bauernfeind F, Hartmann G, et al. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol 2009;10(10):1065–1072.
51. Yang P, An H, Liu X, et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat Immunol 2010;11(6):487–494.
52. Kondo T, Kobayashi J, Saitoh T, et al. DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A 2013;110(8):2969–2974.
53. Kim T, Pazhoor S, Bao M, et al. Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 2010;107(34):15181–15186.
54. Fernandes-Alnemri T, Yu JW, Juliana C, et al. The AIM2 inflammasome is critical for innate immunity to Francisellatularensis. Nat Immunol 2010;11(5):385–393.
55. Sun L, Wu J, Du F, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013;339(6121):786–791.
56. Wu J, Sun L, Chen X, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA Science 2013.;339(6121):826–830.
57. Li XD, Wu J, Gao D, et al. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 2013;341(6152):1390–1394.
58. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006;441(7089):101–105.
59. van Heel DA, Ghosh S, Butler M, et al. Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol 2005;35(8):2471–2476.
60. Fritz JH, Girardin SE, Fitting C, et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol 2005;35(8):2459–2470.
61. Uehara A, Yang S, Fujimoto Y, et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol 2005;7(1):53–61.
62. Tada H, Aiba S, Shibata K, et al. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 2005;73(12):7967–7976.
63. Saiga H, Shimada Y, Takeda K, Innate immune effectors in mycobacterial infection. Clin Dev Immunol 2011;2011:347594.
64. Gandotra S, Jang S, Murray PJ, et al. Nucleotide-binding oligomerization domain protein 2-deficient mice control infection with Mycobacterium tuberculosis. Infect Immun 2007;75(11):5127–5134.
65. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278(11):8869–8872.
66. Geijtenbeek TB, Gringhuis SI, Signalling through C-type lectin receptors:shaping immune responses. Nat Rev Immunol 2009;9(7):465–479.
67. Marakalala MJ, Graham LM, Brown GD. The role of Syk/CARD9-coupled C-type lectin receptors in immunity to Mycobacterium tuberculosis infections. Clin Dev Immunol 2010;2010:567571.
68. Yonekawa A, Saijo S, Hoshino Y, et al. Dectin-2 is a direct receptor for mannose-capped lipoarabinomannan of mycobacteria. Immunity 2014;41(3):402–413.
69. Gross O, Gewies A, Finger K, et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 2006;442(7103):651–656.
70. Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase:a crucial player in diverse biological functions. Nat Rev Immunol 2010;10(6):387–402.
71. Poeck H, Bscheider M, Gross O, et al. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol 2010;11(1):63–69.
72. Dorhoi A, Desel C, Yeremeev V, et al. The adaptor molecule CARD9 is essential for tuberculosis control. J Exp Med 2010;207(4):777–792.
73. Zhang SY, Jouanguy E, Ugolini S, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007;317(5844):1522–1527.
74. Yang K, Puel A, Zhang S, et al. Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 2005;23(5):465–478.
75. Tartey S, Takeuchi O. Toll-like receptors:role in inflammation and cancer. In Cancer and Inflammation Mechanisms:Chemical, Biological, and Clinical Aspects; 2014. pp. 83–102.
76. Balkwill F, Mantovani A. Inflammation and cancer:back to Virchow? Lancet 2001;357(9255):539–545.
77. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4(1):71–78.
78. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454(7203):436–444.
79. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta:“N1” versus “N2” TAN. Cancer Cell 2009;16(3):183–194.
80. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140(6):883–899.
81. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362(10):875–885.
82. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141(1):39–51.
83. Cortez-Retamozo V, Etzrodt M, Newton A, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A 2012;109(7):2491–2496.
84. Shcheblyakov DV, Logunov DY, Tukhvatulin AI, et al. Toll-like receptors (TLRs):the role in tumor progression. Actanaturae 2010;2(3):21–29.
85. Garay RP, Viens P, Bauer J, et al. Cancer relapse under chemotherapy:why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007;563(1–3):1–17.
86. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991(262):3–11.
87. Salaun B, Zitvogel L, Asselin-Paturel C, et al. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res 2011;71(5):1607–1614.
88. Miyake T, Kumagai Y, Kato H, et al. Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways. J Immunol 2009;183(4):2522–2528.
89. Akazawa T, Ebihara T, Okuno M, et al. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A 2007;104(1):252–257.
90. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011;470(7335):543–547.
91. Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007;316(5831):1628–1632.
92. Cluff CW., Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines:clinical results. Adv Exp Med Biol 2009;667:111–123.
93. Cai Z, Sanchez A, Shi Z, et al. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 2011;71(7):2466–2475.
94. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008;320(5873):226–230.
95. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5(6):471–484.
96. Shatz M, Menendez D, Resnick MA. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res 2012;72(16):3948–3957.
97. Tye H, Kennedy CL, Najdovska M, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012;22(4):466–478.
98. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system:a treasure trove for drug development. Nat Rev Drug Discov 2004;3(1):17–26.
99. Kim S, Takahashi H, Lin WW, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009;457(7225):102–106.
100. Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and cancer. Ann Rev Immunol 2010;28:367–388.
101. Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21(4):504–516.
102. Srivastava K, Srivastava A, Kumar A, et al. Significant association between toll-like receptor gene polymorphisms and gallbladder cancer. Liver Int 2010;30(7):1067–1072.
103. Rigoli L, DiBella C, Fedele F, et al. TLR4 and NOD2/CARD15 genetic polymorphisms and their possible role in gastric carcinogenesis. Anticancer Res 2010;30(2):513–517.
104. Kutikhin AG, Impact of Toll-like receptor 4 polymorphisms on risk of cancer. Hum Immunol 2011;72(2):193–206.
105. Song EJ, Kang MJ, Kim YS, et al. Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int J Mol Med 2011;28(1):115–119.
106. Kim WY, Lee JW, Choi JJ, et al. Increased expression of toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer 2008;18(2):300–305.
107. Droemann D, Albrecht D, Gerdes J, et al. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 2005;6:1.
108. Ilvesaro JM, Merrell MA, Swain TM, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007;67(7):774–781.
109. Cherfils-Vicini J, Platonova S, Gillard, M, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010;120(4):1285–1297.
110. Bartel DP. MicroRNAs:target recognition and regulatory functions. Cell 2009;136(2):215–233.
111. Ambros V. microRNAs:tiny regulators with great potential. Cell 2001;107(7):823–826.
112. Fabbri M, Croce CM. Role of microRNAs in lymphoid biology and disease. Curr Opin Hematol 2011;18(4):266–272.
113. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10(10):704–714.
114. Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 2012;109(31):E2110–E2116.
115. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3(2):196–200.
116. Dudek AZ, Yunis C, Harrison LI, et al. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 2007;13(23):7119–7125.
117. Dummer R, et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008;14(3):856–864.
118. Boonstra A, et al. Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7. Antivir Ther 2012;17(4):657–667.
119. Horak F. VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs 2011;20(7):981–986.
120. Drachenberg KJ, et al. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56(6):498–505.
121. Czeslick E, et al. E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes. Inflamm Res 2006;55(11):511–515.
122. Murata M. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci 2008;99(7):1435–1440.
123. Wurfel MM, et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med 2008;178(7):710–720.
124. Schuring RP, et al. Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. J Infect Dis 2009;199(12):1816–1819.
125. Johnson CM, et al. Cutting edge:A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol 2007;178(12):7520–7524.
126. Kang TJ, Lee SB, Chae GT. A polymorphism in the toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine 2002;20(2):56–62.
127. Ogus AC, et al. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004;23(2):219–223.
128. Schroder NW, et al. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borreliaburgdorferi and protects from late stage Lyme disease. J Immunol 2005;175(4):2534–2540.
129. Tabel Y, Berdeli A, Mir S. Association of TLR2 gene Arg753Gln polymorphism with urinary tract infection in children. Int J Immunogenet 2007;34(6):399–405.
130. Lorenz E, et al. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000;68(11):6398–6401.
131. Castro FA, et al. TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer 2011;47(8):1203–1210.
132. Zhou P, et al. Toll-like receptor 3 C1234T may protect against geographic atrophy through decreased dsRNA binding capacity. FASEB J 2011;25(10):3489–3495.
133. Sironi M, et al. A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. J Immunol 2012;188(2):818–823.
134. Kiechl S, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347(3):185–192.
135. Agnese DM, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002;186(10):1522–1525.
136. Pierik M, et al. Epithelioid granulomas, pattern recognition receptors, and phenotypes of Crohn's disease. Gut 2005;54(2):223–227.
137. Hawn TR, et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med 2003;198(10):1563–1572.
138. Hawn TR, et al. A stop codon polymorphism of toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc Natl Acad Sci U S A 2005;102(30):10593–10597.
139. Hoffjan S, et al. Evaluation of the toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease. BMC Med Genet 2005;6:34.
140. Kesh S, et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci 2005;1062:95–103.
141. Sales ML, et al. Toll-like receptor 6 Ser249Pro polymorphism is associated with lower left ventricular wall thickness and inflammatory response in hypertensive women. Am J Hypertens 2010;23(6):649–654.
142. Askar E, Ramadori G, Mihm S. Toll-like receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C virus infection. J Med Virol 2010;82(11):1859–1868.
143. Oh DY, et al. A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. AIDS 2009;23(3):297–307.
144. Shen N, et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A 2010;107(36):15838–15843.
145. Schott E, et al. A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol 2007;47(2):203–211.
146. Engin A, et al. Toll-like receptor 8 and 9 polymorphisms in Crimean-Congo hemorrhagic fever. Microbes Infect 2010;12(12–13):1071–1078.
147. Davila S, et al. Genetic association and expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis. PLoS Genet 2008;4(10):e1000218.
148. Carvalho A, et al. The C allele of rs5743836 polymorphism in the human TLR9 promoter links IL-6 and TLR9 up-regulation and confers increased B-cell proliferation. PLoS One 2011;6(11):e28256.
149. Sam-Agudu NA, et al. TLR9 polymorphisms are associated with altered IFN-gamma levels in children with cerebral malaria. Am J Trop Med Hyg 2010;82(4):548–555.
150. Zhou XJ, et al. Association of TLR9 gene polymorphisms with lupus nephritis in a Chinese Han population. Clin Exp Rheumatol 2010;28(3):397–400.
151. Pandey S, et al. Evaluation of Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility. Mol Biol Rep 2011;38(7):4715–4721.
152. Lazarus R, et al. TOLL-like receptor 10 genetic variation is associated with asthma in two independent samples. Am J Respir Crit Care Med 2004;170(6):594–600.